The findings from the current study not only further confirm the role of mitochondrial dysfunction in diabetic kidney disease, but also offer the potential of targeting KCa3.1 to normalize mitochondrial quality control in the treatment of diabetic kidney disease. This evidence concerns the gene KCNN4 and diabetic kidney disease.